Includes foreign distribution status, completed professional video, upcoming steps in XPRIZE competition, production and signed partner updates
LOS ANGELES, CA / ACCESSWIRE / October 13, 2020 / Decision Diagnostics Corp. (OTC PINK: DECN) www. decisiondiagnostics. co, the world’s leading manufacturer and distributor of diabetic control strips designed to operate on legacy glucometers through its subsidiary Pharma Tech Solutions, Inc. , provided the following “progress update” on its ongoing efforts to download FDA USA approval for its Covid-19 Saliva Swift Kit antigen verification, foreign distribution prestige and other corporate developments.
Late last month, the company announced that it had signed an agreement with an FDA- and CLIA-certified test spouse in the US. But it’s not the first time To adopt a feasibility test and testing required for the US certification of the FDA and the CE mark of the European Union, as well as with the Russian Federation for the presentation of the GenViro!Covid-19 Saliva Swift Kit. The effects of the lab will be included in the FDA’s upcoming US DECN programs expected to be introduced in the fourth quarter of 2020. Corporate plans are parallel programmes with the EU and the Russian Federation, while continuing their efforts abroad to ensure that their sensor generation is around the world. .
“Based on the checks done through our Korean spouse, we have one and both explanations of why we believe that our U. S. spouse will see similar effects and report that GenViro!Satisfied (and most likely outweighs) the FDA’s needs to off discharge U. S. approval,” CEO Keith Berman said. “We are encouraged by the progress and speed that society is seeing on a variety of critical fronts and remain focused on the good fortune of both, as temporarily as imaginable, to pursue our overall goals of delivering this promising check solution to markets around the world.
In addition to upcoming FDA testing, the company announced that it had won its first written order from an Indian distributor. The first of several expected follow-up requests turned out to be much larger than advertised and includes 500,000 Genviro!Saliva Swift Kits, 50,000 GenViro!Swift Verify Kits and 7500 GenViro! Swift Kit counters. The company expects production to begin in a while and more product distribution opportunities are being prepared in Malaysia, Indonesia, the Russian Federation and the EU.
As distribution and production efforts progress, the company also reported that it has produced two videos of vital professional use instructions that will incorporate GenViro. The Saliva Swift Covid-19 kit will be announced in the United States and abroad. commands that professionals will have to stick to to get the maximum precise effects for each test. The videos are lately ready in English, as well as with subtitles in Russian, German, French, Spanish and Hindi, along with other adaptations of the video in Bahasa melayu The videos are posted on the Pharma Tech Solutions, Inc. : https://www. pharmatechsolutions. co/genviro. html
While a spouse’s signature on US checks was in the process of underwriting and extensive verification has already been conducted and is proceeding in Korea, DECN will also move to a third verification circular in Korea together with the company that She was selected. as an XPRIZE semi-finalist, www. xprize. org. XPRIZE is the world leader in the design and operation of incentive conchecks to solve humanity’s wonderful and demanding situations. It works in collaboration with OpenCovidScreen, a non-profit organization founded by scientists and business leaders, to stimulate mandatory innovation through “open science”. XPRIZE, OpenCovidScreen, and a coalition of spouses are calling on the global network to expand common, fast, reliable, and easy-to-use screening checks to detect Covid-19 cases before outbreaks occur. The five million dollar XPRIZE Rapid Covid Testing festival is designed to drive the progression of fast, accurate, easy-to-use, and high-quality turnacircular Covid-19 controls, enabling common control. To meet XPRIZE requirements, DECN will verify samples containing synthetic blood, which approximates a non-inflamed sample, and synthetic blood that approximates COVID-inflamed samples, the samples of which will be provided through the organization. The effects will take place once the XPRIZE committee announces its winning selection. The organization plans to report on the grand prize winners in the first quarter of 2021.
Finally, the company confirms that it will first manufacture 3 retail products for professional use abroad: First, GenViro! Saliva Swift Kit which adds 1 control strip, interface sleeve adapter, saliva collection container, diluent, packaging inserts that will retail for $ 8. 95 in bulk with an MSRP of $ 29. 95. The GenViro! Swift Kit Meter will come with 1 meter for up to one hundred verification readings, an automated instructional video, which can also be viewed online at www. pharmatechdirect. com, a meter user manual, and a package insert. ‘packaging. The meter will wholesale for $ 19. 95 with an MSRP of $ 39. 95 and will come with an owner’s manual, a leaflet, and the aforementioned DVD containing the company’s GenViro. instructional videos. The GenViro! The Swift Verify kit comes with 1 check strip, interface sleeve adapter, and leaflet. This kit is designed to provide a Covid-19 follow-up check if desired. The GenViro! The Swift Verify Kit will retail for $ 6. 95 in bulk with an MSRP of $ 24. 95.
ABOUT DECISION DIAGNOSTICS CORP
Decision Diagnostics Corp. es the world’s leading manufacturer and distributor of diabetic control strips designed to paint on classic glucometers. DECN products are designed to successfully and cost-effectively paint safe glucometers that are already used in nearly 7. 5 million diabetics worldwide. Diabetic check strips already in the latter stages of development, DECN products compete globally with classic brands that lately sell more than 71% of a home check market of more than $15 billion.
The company’s new GenViro!™ products designed to verify Covid-19 are not yet available in the US. But it’s not the first time Or Puerto Rico, but emergency exemptions (U. S. ) are ongoing with the U. S. FDA. But it’s not the first time And more presentations will be made in the near future. The company has also signed an agreement with an FDA-qualified check spouse and U. S. CLIA. But it’s not the first time To conduct verifications in accordance with existing FDA rules and continues to await FDA approval from our U. S. FDA. But it’s not the first time
The same knowledge that will be produced through the new component of the company will be used for submissions to the EU and the Russian Federation. We will also use the knowledge provided through our Korean component as a component of the XPRIZE initiative.
The company continues to recruit and conform to programs of potential domestic and foreign distributors. Inquiries can be directed to info@decisiondiagnostics. co.
Forward-looking statements:
In this press release, the Company’s forward-looking statements are based on the management’s existing expectations and assumptions as of October 12, 2020, related to the Company’s business and performance, prospects, existing factors, economy and other long-term situations, and long-term event forecasts. cases and results.
CONTACT INFORMATION:
CONTACT INFORMATION:
SOURCE: Decision Diagnostics Corp.